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Objectives: Febrile neutropenia (FN) causes treatment disruption and unplanned
hospitalization in children with cancer. Serum biomarkers are infrequently used to
stratify these patients into high or low risk for serious infection. This study investigated
plasma abundance of cytokines in children with FN and their ability to predict bacteraemia.
Methods: Thirty-three plasma cytokines, C-reactive protein (CRP) and procalcitonin
(PCT) were measured using ELISA assays in samples taken at FN presentation (n = 79)
and within 8–24 h (Day 2; n = 31). Optimal thresholds for prediction of bacteraemia were
identified and the predictive ability of biomarkers in addition to routinely available clinical
variables was assessed.
Results: The median age of included FN episodes was 6.0 years and eight (10%) had a
bacteraemia. On presentation, elevated PCT, IL-10 and Mip1-beta were significantly
associated with bacteraemia, while CRP, IL-6 and IL-8 were not. The combination of PCT
(≥0.425 ng/ml) and IL-10 (≥4.37 pg/ml) had a sensitivity of 100% (95% CI 68.8–100%)
and specificity of 89% (95% CI 80.0–95.0%) for prediction of bacteraemia, correctly
identifying all eight bacteraemia episodes and classifying 16 FN episodes as high-risk.
There was limited additive benefit of incorporating clinical variables to this model. On Day
2, there was an 11-fold increase in PCT in episodes with a bacteraemia which was
significantly higher than that observed in the non-bacteraemia episodes.org May 2021 | Volume 12 | Article 6418791
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Frontiers in Immunology | www.frontiersin.Conclusion: Elevated PCT and IL-10 accurately identified all bacteraemia episodes in our
FN cohort and may enhance the early risk stratification process in this population.
Prospective validation and implementation is required to determine the impact on
health service utilisation.Keywords: cancer, children, febrile neutropenia, biomarkers, risk stratificationINTRODUCTION
Infection, frequently presenting as fever and neutropenia (FN), is
the leading cause of unplanned hospital admissions for
administration of broad spectrum antibiotics in children with
cancer (1). There is a growing international effort to optimise the
management of children with cancer and FN through the use of
risk stratification strategies (2). This is in recognition of the
heterogenous nature of FN and the data to support that a large
proportion of children with FN are low-risk of severe infection or
adverse outcome (2, 3).
Early de-escalation of standard inpatient care and cessation of
intravenous antibiotics in patients identified as low-risk has been
shown to reduce antibiotic exposure and hospital length of stay and
improvement in quality of life (4–6). Ensuring these management
pathways have the greatest impact without compromising patient
safety, relies on the early (<24 h) and accurate identification of
children with low-risk FN (7). To date, much of the attention has
focused on the derivation and validation of decision rules
incorporating readily available laboratory and clinical parameters
to predict infection or adverse outcome and the role of novel
biomarkers in augmenting these rules, remains unknown (8).
Studies in children with cancer and FN have explored the
value of a range of inflammatory cytokines in isolation in
predicting infection and complications (9, 10). An updated
systematic review found that interleukin (IL)-6, IL-8, C-
reactive protein (CRP) and procalcitonin (PCT) were
predictive of bacteraemia and severe sepsis as compared to a
range of other biomarkers however the optimal thresholds in FN
remain unknown (11). While the role of serial biomarkers has
also been explored, the few studies that have investigated the
diagnostic performance of cytokines at presentation and Day 2
have mixed results (11).
The objectives of this study were to compare and contrast the
ability of an extended range of 34 serum cytokines, in addition to
more commonly available PCT and CRP, to predict bacteraemia
in children with cancer and FN. We also explored the trend of
these biomarkers on Day 2 as well as the additional predictive
value these biomarkers have over or in combination with
routinely available clinical data.MATERIALS AND METHODS
Patient Recruitment and Blood Sample
Collection
This prospective biomarker study was embedded into the
Australian Predicting Infectious ComplicatioNs In Childrenorg 2with Cancer (PICNICC) study (Australian New Zealand
Clinical Trials Registry 12616001440415) (12). The Australian
PICNICC study is a large, multisite, prospective study designed
to validate existing paediatric FN clinical decision rules (CDRs)
and identify novel biomarkers that predict severe infection (12,
13). Patients were enrolled at two of the eight study sites: Royal
Children’s Hospital (RCH), Melbourne and Queensland
Children’s Hospital (QCH), Brisbane.
Children with solid-organ cancer or leukaemia on active
treatment and who presented to the emergency department
with FN were included. Multiple, discrete FN episodes per
patient were allowed. Fever was defined as a single tympanic
temperature ≥38 °C and neutropenia was defined as an absolute
neutrophil count (ANC) <1,000/mm3. Children with
hematopoietic stem cell transplant (HSCT) within three
months and those receiving treatment antibiotics were
excluded. Demographic, FN episode and outcome data were
prospectively collected by the site research assistant (RA) from
electronic and paper-based records and entered into research
electronic data capture (REDCap).
To optimise patient recruitment, the electronic medical
record (Epic) was utilised at one site (RCH). A Best Practice
Alert (BPA) was developed that identified cancer patients on
active treatment and who presented to the emergency
department with fever and who had a valid RCH Children’s
Cancer Centre (CCC) tissue bank patient consent. The BPA fired
when the treating clinician ordered blood samples and included
the following statement: “This patient has consented to provide
samples to the CCC Tissue Bank and presents with possible
febrile neutropenia—please order the required CCC Tissue Bank
sample.” An option for not-eligible or declined sample was
included on the alert.
Blood from eligible patients was collected at two time points:
FN onset (within 0–4 h of ED presentation and prior to the first
dose antibiotic) and Day 2 (within 8–24 h of ED presentation).
Blood was collected in EDTA tubes and processed by the cancer
centre’s tissue banks at RCH and QCH according to a
standardised protocol. Within two hours of sample collection,
plasma was separated from erythrocytes and peripheral blood
mononuclear cells (PBMCs) using Ficoll density gradient
centrifugation and stored at −80°C until thawed for
biomarker analysis.
The primary outcome was bacteraemia and defined according
to paediatric FN research consensus definitions (see Table 1)
(16). All infection diagnoses were made from clinical symptoms
or microbiological samples taken within 48 h of FN onset.
Microbiological investigations were performed according to
site FN guidelines. Across both sites this included: at least oneMay 2021 | Volume 12 | Article 641879
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commenced) and urine for culture; nasal swab for respiratory
virus PCR; chest X-ray; stool for culture, Clostridioides difficile
toxin assay and viral PCR; and skin or wound swab for culture
and viral PCR (as indicated) (Table 1).
The additive predictive ability of biomarkers to routinely available
clinical variables was assessed. Clinical variables previously identified
to be predictive of bacterial infection in the Australian PICNICC
dataset were used and included: height of temperature, platelet count
and clinically unwell (13). Clinically unwell was defined as severe
sepsis or septic shock (as per Goldstein et al.) (15), altered conscious
state (Glasgow Coma Score <15 or only responsive to voice or pain),
documented as ‘severely unwell’ or equivalent in patient record or
either blood pressure or respiratory rate within the Victorian age-
based mandatory emergency call range (12).
The additive predictive ability of the commercially available
PCT to the recalibrated CDR that showed the best performance
in the Australian PICNICC study dataset (AUS-rule) was also
determined (13). The AUS-rule uses three clinical variables
(platelets <50 g/L, total white cell count <300 cells/m3 and
chemotherapy more intensive than acute lymphoblastic
leukaemia-maintenance phase) each with a weighted value of
‘1’ to predict bacterial infection in children with cancer and FN.
The rule has been validated internationally (14) and is being
implemented across Australia (ACTRN12616001440415).
Blood Plasma Biomarker Analysis
Procalcitonin (PCT) and C-Reactive Protein (CRP)
Analysis
PCT in patient plasma was quantified using the COBAS Elecsys
BRAHMS electrochemiluminescence immunoassay “ECLIA” on
the COBAS e 801 immunoassay analyzer. CRP was quantified
using VITROS Chemistry Products CRP Slides and the VIRTOS
250/350 system according to the manufacturers instruction.
Multiplex Plasma Cytokine ELISA Analysis
The Human Cytokine & Chemokine 34-plex ProcartaPlex 1A
multiplex immunoassay kit (Invitrogen/Thermo #EPX340-
12167-901) was used to assay the abundance of the following
plasma cytokines: Eotaxin/CCL11; GM-CSF; GRO alpha/
CXCL1; IFN alpha; IFN gamma; IL-1 beta; IL-1 alpha; IL-1RA;Frontiers in Immunology | www.frontiersin.org 3IL-2; IL-4; IL-5; IL-6; IL-7; IL-8/CXCL8; IL-9; IL-10; IL-12 p70;
IL-13; IL-15; IL-17A; IL-18; IL-21; IL-22; IL-23; IL-27; IL-31; IP-
10/CXCL10; MCP-1/CCL2; MIP-1 alpha/CCL3; MIP-1 beta/
CCL4; RANTES/CCL5; SDF1 alpha/CXCL12; TNF alpha; TNF
beta. As per manufacturers instruction, 25 µl of each sample were
thawed and stained with the respective cytokine bead mix and
samples run on the Bio-plex 200 system (Bio-Rad Laboratories,
USA). Data for a total of 33 cytokines was obtained, however,
TNF beta ELISA measurements could not be obtained. Cytokine
concentrations were calculated using Bio-Plex Manager 5.0
software (Bio-Rad Laboratories, USA) with a five-parameter
curve-fitting algorithm applied for standard curve calculations.
Statistical Analysis
To determine if the subset of patients with a blood sample taken
is representative of the entire RCH and QCH cohort the
following characteristics were compared: median age, sex,
diagnosis, infective diagnosis, severe sepsis, intensive care unit
(ICU) admission, median length of stay (LOS), death. The
Youden and Liu method for cut-point analysis of receiver
operator curves (ROC) was used to define the value that best
predicts bacteraemia for each plasma biomarker molecule by
optimally balancing sensitivity and specificity. Predictive cut off
values as well as positive and negative predictive values were
calculated based on this Youden ROC analysis. Analyses were
performed using Graphpad prism v8.
A classification tree was constructed to identify patients with
bacteraemia from the serum cytokine measurements and clinical
data (17). To increase sensitivity and to balance the influence of
bacteraemia vs non-bacteraemia episodes, a loss matrix was
incorporated to weight the cost of misclassification for false
negatives as 10 times more than that for false positives. To avoid
very small partitions, the minimum number of observations in a
node was set to 10. The estimated decision tree was pruned based
on a complexity parameter of 0.01. In order to estimate the
predictive misclassification rate, the final model was validated
using cross-validation whereby each patient was excluded from
the data in turn to train the model on the remaining patients and
predictions made for the observations from that patient. The
optimal recursive partitioning of the predictor variables was
estimated using the rpart package (18) in R 4.0.0 (19).TABLE 1 | Definitions of outcomes included in analysis.
Outcome Definition
Bacteraemia (14) A recognised bacterial pathogen (including organisms associated with mucosal barrier injury in the setting of mucositis or neutropenia) from




An infection that was clinically detectable and microbiologically proven.
Clinically documented
infection (CDI) (14)
A site of infection that is diagnosed but its microbiological pathogenesis either cannot be proven or is inaccessible to examination.
Fever of unknown
origin (FUO) (14)
Any febrile episode without a clinically detectable and microbiologically proven infection.
AUS-rule (15) A paediatric FN clinical decision rule that incorporates three clinical variables (platelets <50 g/L, total white cell count <300 cells/m3 and
chemotherapy more intensive than acute lymphoblastic leukaemia-maintenance phase) each with a weighted value of ‘1’ to predict bacterial
infection. AUS-rule scores range from 0 to a maximum of 3.
End of FN episode Afebrile for more than 48h, recovery of ANC beyond nadir and antibiotic cessation.May 2021 | Volume 12 | Article 641879
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Characteristics of FN Episodes
Blood samples for cytokine analysis were taken at presentation
(between 0 and 4 h) in 80 out of 553 FN episodes, enrolled at
RCH and QCH as part of the Australian PICNICC study
(RCH n = 68; QCH n = 12). Sufficient serum for analysis was
unavailable for one patient leaving 79 samples occurring in 64
patients (12 patients had two FN episodes, two patients had three
FN episodes). In 31 episodes, a second sample was taken at Day 2
(between 8 and 24 h from presentation). The median time
between Presentation and Day 2 sample was 21.5 h (IQR:
18.25–23.3 h, range 6.83–30.25). All FN episodes had blood
cultures collected prior to the first dose antibiotic.
The median age of patients with a blood sample taken was 6.0
years, slightly higher than those without a sample taken.
Otherwise there was no significant difference in baseline
demographics, causes of infection and clinical complications
between the FN episodes with and without a blood sample
taken (Table 2), as well as between episodes with blood sample
taken at Days 1 and 2 (data not shown). Of the eight (10%)
episodes with a bacteraemia, three were gram-positive and fiveFrontiers in Immunology | www.frontiersin.org 4were gram negative. Two FN episodes were admitted to ICU (at
Days 1 and 11), one of which was diagnosed with severe sepsis.
Plasma Cytokine, CRP and PCT Profiles at
FN Presentation
Plasma CRP and PCT levels as well as the abundance of 33 plasma
cytokines and chemokines from 79 FN episodes with blood taken
at time of FN presentation (Day 1) were quantified. The mean PCT
(p = 0.0016), IL-10 (p = 0.0041) and Mip1-beta (p = 0.0078) values
were significantly higher in episodes with bacteraemia than those
without bacteraemia at FN presentation (Day 1) (Supplementary
Table 1). In contrast, mean values of CRP as well as all other
cytokines and chemokines including IL-6 and IL-8 were not
significantly different in episodes with and without bacteraemia
(Supplementary Table 1). The area under the curve (AUC),
optimal threshold values, sensitivity, specificity and positive and
negative likelihood ratios for CRP, PCT and the cytokines IL-6,
IL-8, IL-10 and MIP1-beta are summarized in Table 3.Additive Performance of Biomarkers and
Clinical Variables at Presentation
The additive performance of PCT, IL-10 and Mip1-beta was
assessed in combination and together with individual clinical
variables (platelets, maximum temperature and/or clinically
unwell) that had been shown to predict bacteraemia in this
cohort (13). Using a classification model based on a decision tree,
the highest specificity and sensitivity was observed when
combining PCT (threshold ≥0.425 ng/ml) and IL-10 (threshold
≥4.37 pg/ml) (Figure 1A). If this combination of biomarkers
were used in isolation to risk stratify patients, 16 episodes would
be classified as high-risk of which eight (50%) had a bacteraemia
(Figures 1A, B). Conversely, 63 (80%) episodes would be
classified as low-risk, none of which had a bacteraemia. The
combined PCT/IL-10 model had a sensitivity of 100% (95% CI
68.8–100%) and specificity of 89% (95% CI 80.0–95.0%) for
prediction of bacteraemia. Cross-validation, which trains and
assesses the predictor on independent data subsets, reduced the
estimated sensitivity slightly to 87.5% (47.3–99.7%) and the
specificity to 87.3% (77.3–94.0%). Of these 16 ‘high-risk’
episodes, one episode with bacteraemia (Escherichia coli) also
had severe sepsis at FN presentation and was admitted to the
ICU within 4.2 h. Of these 63 ‘low-risk’ episodes, one child was
admitted to ICU with a late clinical deterioration, 11 days
following initial FN presentation.
Adding clinical variables (platelets, maximum temperature and/
or clinically unwell) into this classificationmodel, either individually
or in any combination, did not improve the predictive performance
of the PCT and IL-10 biomarker combination.
The added diagnostic value of PCT and IL-10 to the AUS-rule
CDR was also assessed. Using the AUS-rule in isolation and with
a low-risk threshold set at ‘0,’ bacteraemia was correctly ruled out
in only 10 (13%) FN episodes. Incorporating PCT (threshold
<0.425 ng/ml = low risk) to the AUS-rule for scores of ‘1’ or
above, a further 49 FN episodes (total 59, 75%) were correctly
classified as ‘low-risk’ (Table 4). Incorporating both PCT and IL-
10 to the AUS-rule for scores of ‘1’ or above, a further 7 FNTABLE 2 | Demographic and outcome data of FN episodes.
FN episodes
without blood
sample (n = 473)
FN episodes with
blood sample at Day




4.3 (2.9–8.4) 6.0 (3.4–11.3) 0.043




260 (55.0) 49 (62.0) 0.271




4 (0.9) 1 (1.3) 0.548
ICU admission, n
(%)
15 (3.2) 2 (2.5) >0.99
Infection
diagnosis
–Bacteraemia 66 (14.0) 8* (10.1) 0.14
–Other MDI 90 (19.0) 22 (27.8)
–CDI 44 (9.3) 11 (13.9)




6.3 (2.8–12.2) 4.9 (2.5–9.1) 0.04
Median hospital
LOS, days (IQR)
6.0 (3.1–13.3) 5.13 (3.0-7.6) 0.07
Died within 30
days
2 (0.4) 0 >0.99FN, febrile neutropenia; IQR, interquartile range; ICU, intensive care unit; MDI,
microbiologically defined infection; CDI, clinically defined infection; FUO, fever of
unknown cause; LOS, length of stay.
*Gram negative (Klebsiella pneumoniae/Pseudomonas aeruginosa, Escherichia fergusonii,
Neisseria lactamica, Pseudomonas species, Escherichia coli) and Gram positive
(Staphylococcus epidermidis, Enterococcus faecium, Enterococcus faecalis).May 2021 | Volume 12 | Article 641879
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compared to using the AUS-rule and PCT alone. Similar to the
combined PCT and IL-10 decision tree above, the FN episode
without a bacteraemia but with a late onset clinical deterioration
(day 11) would be classified as low risk using this approach.Frontiers in Immunology | www.frontiersin.org 5Plasma Cytokine, CRP and PCT Profiles at
Day 2
Plasma levels of CRP, PCT and 33 cytokines and chemokines
from 31 of the 79 episodes that had a repeat blood sample taken
at Day 2 (8–24 h from presentation) were available for analysisTABLE 3 | Performance of biomarkers to predict bacteraemia at FN presentation (Day 1).
AUC p-value Threshold Sensitivity% (95% CI) Specificity% (95% CI) Positive LR Negative LR Youden Index
PCT 0.842 0.002 >0.425 [ng/ml] 100 (68–100) 78 (67–86) 4.5 0 0.77
IL-10 0.826 0.003 >16.66 [pg/ml] 75.0 (41–96) 82 (71–89) 4.2 0.3 0.57
MIP1-beta 0.780 0.010 >52.79 [pg/ml] 63 (31–86) 90 (81–95) 6.3 0.4 0.53
CRP 0.695 0.073 >62.5 [ug/ml] 50 (22–79) 78 (67–86) 2.3 0.6 0.27
IL-6 0.625 0.249 >356 [pg/ml] 50 (22–79) 90 (81–95) 5 0.6 0.40
IL-8 0.666 0.127 >665.5 [pg/ml] 50 (22–79) 80 (70–88) 2.5 0.6 0.30May 2021 | Volume 12 |AUC, Area Under the Curve; CI, Confidence interval; LR, likelihood ratio.A B
FIGURE 1 | Decision tree classification model including PCT and IL-10. (A) Scatterplot showing distribution of IL-10 and PCT values of Day 1 samples. Red-
bacteraemia cases, grey-no bacteraemia. (*) depicts ICU admission, (#) depicts severe sepsis diagnosis. (B) Decision tree model to identify low risk and high risk
episodes using PCT and IL-10 with the indicated threshold values.TABLE 4 | Combined performance of AUS-rule and PCT and IL-10 for prediction of bacteraemia episodes in children with febrile neutropenia (shaded area are
episodes classified as low-risk).
Risk status according to AUS-rule
Low risk High Risk Total, n (%)






(PCT <0.425 ng/ml)—no bacteraemia, n
6 21 17 11* 55 (69.6%)
High risk
(PCT ≥0.425 ng/ml)—no bacteraemia, n
4 3 9 0 16 (20.3%)
High risk
(PCT ≥0.425 ng/ml), bacteraemia, n
0 2 2 4^ 8 (10.1%)
Procalcitonin and Interleukin-10
Low risk
(PCT <0.425 ng/ml), no bacteraemia, n
6 21 17 11* 55
(69.6%)
Low risk
(PCT ≥0.425 ng/ml & IL-10 <4.37 pg/ml), no bacteraemia, n
1 1 6 0 8 (10.1%)
High risk
(PCT ≥0.425 ng/ml & IL-10 ≥4.37 pg/ml), no bacteraemia, n
3 2 3 0 8 (10.1%)
High risk (PCT ≥0.425 ng/ml & IL-10 ≥4.37 pg/ml), bacteraemia, n 0 2 2 4^ 8 (10.1%)A
*includes one episode admitted to ICU 11 days after initial presentation with FN; ^includes one episode with severe E. coli bacteraemia, sepsis at presentation and ICU admission.rticle 641879
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(p = 0.0271) and IL-23 (p = 0.0292) were able to distinguish
bacteraemia cases from all other underlying causes of FN with
statistical significance (Supplementary Tables 2 and 3).
Comparison of Biomarker Dynamics
Between FN Presentation (Day 1)
and Day 2
Only PCTwas able to distinguish bacteraemia and non-bacteraemia
FN episodes with statistical significance at both time points (Table 3
and Supplementary Table 3). When comparing the kinetics of
plasma PCT levels in the bacteraemia group, an increase by >11-fold
from Days 1 to 2 (Figure 2) was identified. Mean CRP levels also
increased, albeit at lower amplitude (2-fold) (see Supplementary
Figure 1). In contrast, plasma levels of all 33 analysed cytokines
decreased in bacteraemia cases at Day 2 compared to Day 1 by an
average of 3.6-fold, including IL-10 (5-fold), MIP1-beta (7.1-fold),
IL-6 (6.1-fold), IL-8 (2.4-fold), IFN-alpha (7.7-fold) and IL-23 (2.8-
fold) (Figure 2 and Supplementary Figure 1). In all non-
bacteraemia cases, only a subtle increase in PCT (2-fold) or CRP
(1.8-fold) was identified between Days 1 and 2, as well as onlyminor
decreases in the levels of all cytokines and chemokines tested
(average decrease of 1.2-fold) with IL-1ra (2-fold decrease)
showing the biggest difference between the two time points
(Figure 2, Supplementary Figure 1 and Supplementary Table 4).
DISCUSSION
Early diagnosis of bacteraemia in children with cancer and FN
remains a challenge for modern medicine due to the lack ofFrontiers in Immunology | www.frontiersin.org 6highly sensitive and specific laboratory markers and clinical
signs. This multi-site, prospective study has identified three
biomarkers, IL-10, Mip1-beta as well as the commercially
available PCT, that were able to differentiate children with FN
who had a documented bacteraemia from those who did not at
initial hospital presentation. The combination of an elevated
PCT and IL-10 had a sensitivity of 100% and specificity of 89%
for the prediction of initial bacteraemia, correctly identifying all
bacteraemia episodes and classifying 80% of episodes as low risk
and 20% as high risk. This result is superior to most published
paediatric FN CDRs (3). Furthermore, the addition of PCT and
IL-10 to an existing FN CDR (‘AUS-rule’) increased the ability of
this rule to classify low-risk FN episodes by more than six-fold
(13). These data suggest that biomarkers such as PCT and IL-10
may have a role in enhancing existing CDRs or risk-stratification
strategies in children with cancer and FN.
Consistent with our data, several studies have identified PCT
as a more reliable biomarker compared to CRP for the prediction
of bacterial infection, both at FN presentation as well as in serial
measurements (11). Procalcitonin, which reaches plateau values
within 8–24 h, has been shown to be a useful marker for early
diagnosis of sepsis in adult patients as well as differentiation of
bacterial infection from other causes of inflammation, including
viral infection (18, 20). More recently, studies investigating PCT-
guided antibiotic discontinuation algorithms in predominantly
critically unwell adults, indicate it may be safe, cost-effective and
reduce antibiotic duration in selected patient populations (20,
21). While there are at least 22 studies investigating PCT in
children with cancer and FN, it is not routinely used in practice,
nor has been incorporated into published risk stratification
strategies (11). Heterogeneity in laboratory techniques and
outcome definitions, as well as small sample sizes may, in part,
explain this and could be overcome by individual participant
data metanalyses as have been successfully used in other areas of
FN research (2) Prospective validation and implementation
studies are urgently required to determine the diagnostic role
of PCT in the FN population.
Interleukin-10, an anti-inflammatory cytokine, has a crucial
role in limiting the immune response to infection thereby
preventing inflammation and excessive damage to the host
(22) Several groups have previously identified prognostic
values for IL-10 for prediction of bacteraemia, either on its
own in FN in children (23–26) or in combination with PCT in
FN in adult patients (27). However, the vast majority of these
data are generated from small, single centre studies that have
investigated the various markers in isolation. MIP-1beta, a
chemoattractant for a wide range of immune cells, has also
been previously identified as potential biomarker to predict
survival in paediatric septic shock (28) and our study confirms
a potential usefulness for this and IL-10 to be included in future
biomarker studies in FN.
C-reactive protein did not reliably differentiate FN episodes
with and without bacteraemia, either at presentation or Day 2, in
our study. This is consistent with previous studies that show that
CRP as biomarker for serious infections performs poorly in FN
(11). However, despite this, the marker has been usedFIGURE 2 | Mean Plasma PCT and IL-10 levels between time of FN
presentation (Day 1) and Day 2 when comparing bacteraemia cases with all
other causes of FN. P-values shown were calculated using ROC analysis
comparing bacteraemia cases with non-bacteraemia cases at Days 1 and 2.
Data shown as Mean and SEM. **p <0.005, nsp >0.05 (not significant).May 2021 | Volume 12 | Article 641879
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Interleukin-6 and IL-8 were also non-discriminatory for the
prediction bacteraemia in this population. This is in contrast
to other paediatric FN studies, including a FN CDR that
incorporates IL-8 to differentiate patients at high and low-risk
of infection (11, 31). Interleukin-8 has previously also been
demonstrated to rise rapidly in the presence of severe infection
(32) and IL-6 has been proposed as a marker of life-threatening
gram-negative bacterial infections (33) Different outcomes used,
as well as the low number of gram-negative infections in our
group may, in part, explain this difference.
Just as clinical symptoms or signs are rarely used in isolation
to predict infection or adverse outcome, a combination of
different biomarkers may have a role. In our study, all cases of
bacteraemia were detected in FN episodes with elevated PCT and
IL-10. However, while this was statistically validated using a
leave-one-out technique, the overall sample size and proportion
with bacteraemia were small and prospective validation is
essential. The combination of an elevated PCT and IL-10,
albeit at different thresholds, was similarly shown to have a
better predictive ability than the individual markers in 100 adult
patients with haematological malignancy (27). The clinical
impact of using biomarker combinations for risk stratification
is significant, with up to 80% of FN episodes identified as low-
risk in our cohort based on PCT and IL-10 results. These patients
are potentially eligible for reduced intensity FN treatment
including home-based care and oral antibiotics. Using a
structured FN pathway incorporating safety-nets, risk-
stratification has been shown to be safe and significantly
reduce hospital length of stay, antibiotic exposure and costs of
care and improve quality of life (6). While our study has found
that biomarker combinations may be more accurate than
existing CDRs and identify a larger pool of low risk patients,
further studies in addition to validation, are required to explore
feasibility and cost of this approach.
The additive performance of novel biomarkers to routinely
available clinical and laboratory parameters in children with FN
remains unknown. Looking specifically at the clinical variables
shown to predict bacterial infection in the larger Australian
PICNICC study cohort (platelets, elevated temperature and
clinically unwell) we observed no additional benefit to the high
sensitivity and specificity PCT and IL-10 combination (13). A
small benefit was observed when adding PCT and IL-10 to the
AUS-rule, as compared to the PCT and IL-10 combination alone,
with 66 (84%) episodes correctly classified as low-risk compared
to 63 (80%) episodes. This is of particular interest, as the AUS-
rule has been validated internationally and recently implemented
in Australia (15, 19) to predict bacterial infection in children with
cancer and FN.
Analysis of blood samples collected at Day 2 enabled
comparison of biomarkers kinetics. While both PCT and CRP
levels increased in patients with bacteraemia, aligning with
previous reports, a significant difference was only detected for
PCT (13). Interestingly, the overall cytokine levels on Day 2
decreased significantly in bacteraemia episodes compared to the
only subtle decreases observed in the non-bacteraemia episodes.Frontiers in Immunology | www.frontiersin.org 7This may be reflective of a response to antibiotic therapy for
patients with a confirmed bacterial infection and a lack of
response to antibiotic therapy for non-infective or viral causes
of fever. The role of cytokines for monitoring treatment response
in FN warrant further evaluation.
Our prospective, two-centre study provides further insights into
the potential clinical utility of biomarkers, such as the routinely
available PCT, in the paediatric FN risk stratification process. While
our results show some consistencies with previously published data,
our sample size did not permit detailed analysis of impact of gram-
negative versus gram-positive infection. Furthermore, the lower
number of Day 2 samples available for analysis, limit the
conclusion that can be drawn about biomarker kinetics. While we
included additional clinical outcome data such as sepsis and ICU
admissions, the number of these adverse events is also low.
Reassuringly, biomarkers were elevated in the patient with
bacteraemia and severe sepsis at presentation requiring ICU-level
care. However, while the second ICU admission occurring at 11
days was not associated with an elevated PCT at presentation, the
cause of this late clinical deterioration is likely a new event and
would not be expected to be predicted at FN onset. This highlights
the need for any FN risk-stratification process and subsequent
reduced intensity treatment for low-risk patients to include
additional safeguards and clear pathways for readmission or re-
escalation of care.
Currently no paediatric FN CDR can perfectly predict
infections or adverse outcomes in children presenting with FN
(16). Our data generated in a limited cohort of patients supports
the additive value of blood biomarker molecules including PCT
both at presentation and during treatment response. Before
consideration for routine clinical use, prospective validation is
necessary as well as detailed consideration as to the feasibility
and cost-effectiveness of using this approach.DATA AVAILABILITY STATEMENT
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